vTv Therapeutics Announces Initiation of Study Evaluating TTP399’s Potential to Reduce Risk of Diabetic Ketoacidosis in Patients with Type 1 Diabetes
vTv Therapeutics (Nasdaq: VTVT) announced the start of a mechanistic phase 1 study to evaluate TTP399, a liver-selective glucokinase activator, in people with type 1 diabetes. This study focuses on the effects of TTP399 on ketone formation during insulin withdrawal, aiming to demonstrate that it does not increase ketone production, a precursor to ketoacidosis. Previous phase 2 studies showed TTP399 improved glycemic control without raising the risk of ketoacidosis or hypoglycemia. The company plans to initiate a pivotal study later this year.
- Initiation of a phase 1 study for TTP399 targeting health risks in type 1 diabetes.
- Previous studies showed TTP399 improved glycemic control without increasing ketoacidosis or hypoglycemia risks.
- The company plans to begin a pivotal study later this year, indicating progress in drug development.
- None.
HIGH POINT, N.C., March 18, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and inflammatory diseases, today announced the initiation of a mechanistic study exploring the effects of TTP399 on ketone body formation during a period of insulin withdrawal in people with type 1 diabetes. The phase 1 study will test the hypothesis that treatment with vTv’s TTP399, a liver-selective glucokinase activator, will not result in the increased production of ketones, a precursor to ketoacidosis, which can lead to hospitalization in patients with type 1 diabetes.
Despite advances in insulin therapy and monitoring technologies, many patients with type 1 diabetes still do not achieve acceptable glycemic control. Poor glycemic control has resulted in a global increase in hospitalizations for people with type 1 diabetes caused by hypoglycemia or diabetic ketoacidosis. TTP399 previously demonstrated improvement in glycemic control without increased incidence of diabetic ketoacidosis or hypoglycemia in a three-month phase 2 study in patients with type 1 diabetes.
“Developing a drug that does not increase the risk of diabetic ketoacidosis or, even better, has the potential to reduce that risk while improving glycemic control and reducing the risk of hypoglycemia would be a win for patients with type 1 diabetes,” said Steve Holcombe, chief executive officer, vTv Therapeutics. “This would represent a substantial improvement over insulin administration alone.”
The Company continues to push forward with the development of TTP399 in type 1 diabetes and is on track to initiate the first pivotal study later this year.
About Diabetic Ketoacidosis
Diabetic ketoacidosis is a serious condition that occurs when the body produces high levels of blood acids called ketones. It occurs most commonly in patients with type 1 diabetes and has been reported to be the cause for
About vTv Therapeutics
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing oral, small molecule drug candidates. vTv has a pipeline of clinical drug candidates led by programs for the treatment of type 1 diabetes and inflammatory disorders, including psoriasis. vTv’s development partners are pursuing additional indications in type 2 diabetes, chronic obstructive pulmonary disease (COPD), renal disease, and primary mitochondrial myopathy. For more information, please visit www.vtvtherapeutics.com or follow us on Twitter: @vTvTherapeutics.
Forward-Looking Statements
This release contains forward-looking statements, which involve risks and uncertainties. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and, in each case, their negative or other various or comparable terminology. All statements other than statements of historical facts contained in this release, including statements regarding the timing of our clinical trials, our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause our results to vary from expectations include those described under the heading “Risk Factors” in our Annual Report on Form 10-K and our other filings with the SEC. These forward-looking statements reflect our views with respect to future events as of the date of this release and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. These forward-looking statements represent our estimates and assumptions only as of the date of this release and, except as required by law, we undertake no obligation to update or review publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this release. We anticipate that subsequent events and developments will cause our views to change. Our forward-looking statements do not reflect the potential impact of any future acquisitions, merger, dispositions, joint ventures or investments we may undertake. We qualify all of our forward-looking statements by these cautionary statements.
Contacts
Investors:
Corey Davis
LifeSci Advisors
CDavis@LifeSciAdvisors.com
or
Media:
